The complex nature of medicinal plant and animal extracts requires a metabolomic-style approach to determine the active constituents of a product.
Drug Discovery & Development Information
The search for a cure
Modern drug discovery is the convergence of several scientific disciplines to find new medicines to cure disease or relieve suffering. The pharmaceutical pipeline is filled with approximately 5,000-10,000 drug compounds to only one approved commercially available drug. The US FDA CDER (Food & Drug Administration, Center for Drug Evaluation & Research) approves on average only twenty New Molecular Entities (NMEs) per year.
Scientists work to piece together the basic causes of disease at the level of genes, proteins and cells. Out of this understanding emerge “targets,” which potential new drugs might be able to affect.
Drug discovery is multidisciplinary and requires expertise in metabolomics, lipidomics, proteomics, biomarkers, glycomics, antibody analytics, and screening & clone selection.
Drug discovery & development information features
In this webinar, leading experts from Pfizer and Bioanalytix will share their experiences using HDX-MS and other analytical methods in biologic drug development.
KineMed CEO David Fineman explains how they developed proprietary biomarker technology with applications in drug discovery & development.
KineMed's President and Chief Scientific Officer Marc Hellerstein, M.D., Ph.D, explains how the company is building better metrics to help advance medicines for difficult and important diseases based on a biomarker platform.
Watch this whiteboard tutorial to learn about the basics of HPLC and UHPLC.
Drug discovery & development information subtopics
Modern pharmaceutical business drivers are continually pushing to reduce the time it takes to get a product or service to market, reduce the risk and cost associated with that and to improve quality. In laboratories, delivering an analytical result that's right the first time is the answer.